Liver Diseases  >>  GSK 2336805  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK 2336805 / J&J
NCT01424540: Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

Completed
1
20
US
GSK2336805 150mg, Placebo
GlaxoSmithKline
Hepatitis C
10/11
10/11
NCT01458054: Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

Completed
1
28
US
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
GlaxoSmithKline
Hepatitis C
11/11
11/11
NCT01827657: Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

Completed
1
31
US
GSK2336805
GlaxoSmithKline
Hepatitis C
03/14
03/14

Download Options